Join the Ulcerative Colitis group to help and get support from people like you.
Ulcerative Colitis News (Page 2)
Related terms: Colitis, Ulcerative, UC, Colitis Ulcerosa
Subtle Changes Could Predict Inflammatory Bowel Disease Years Before Symptoms Hit
MONDAY, Nov. 13, 2023 (Healthday News) – Inflammatory bowel disease starts to develop years before patients come down with symptoms, a new study suggests. Gut changes can be detected in blood tests...
Inflammatory Bowel Disease Increases Risk for Later Arrhythmias
MONDAY, Nov. 6, 2023 – Patients with inflammatory bowel disease (IBD) overall, as well as Crohn disease (CD) and ulcerative colitis (UC) individually, have an increased risk for developing later...
FDA Approves Wezlana (ustekinumab-auub), an Interchangeable Biosimilar to Stelara
October 31, 2023 – Today, the U.S. Food and Drug Administration approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory...
Monthly News Roundup - October 2023
FDA Clears Loqtorzi as First Treatment for Nasopharyngeal Carcinoma (NPC) In October, the U.S. Food and Drug Administration (FDA) approved Coherus BioSciences’ Loqtorzi (toripalimab-tpzi) to treat a...
FDA Approves Omvoh (mirikizumab-mrkz), a First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis
INDIANAPOLIS, Oct. 26, 2023 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh™ (mirikizumab-mrkz) infusion (300 m...
FDA Approves Zymfentra (infliximab-dyyb) Subcutaneous Formulation for the Treatment of People With Inflammatory Bowel Disease
JERSEY CITY, N.J.--(BUSINESS WIRE) October 23, 2023 --Today, Celltrion USA announced that the U.S. Food and Drug Administration (FDA) has approved Zymfentra (infliximab-dyyb) for maintenance therapy...
ACG: Intestinal Ultrasound Monitoring Cuts Time to Treatment Change in IBD
WEDNESDAY, Oct. 25, 2023 – For patients with inflammatory bowel disease (IBD), monitoring by intestinal ultrasound (IUS) results in reduced time to treatment change and to remission, according to a...
FDA Approves Velsipity for Moderate-to-Severe Ulcerative Colitis in Adults
TUESDAY, Oct. 17, 2023 – The U.S. Food and Drug Administration approved Velsipity (etrasimod) for adults with moderately to severely active ulcerative colitis (UC). The approval was based on results...
FDA Approves Velsipity (etrasimod) for Adults with Moderately to Severely Active Ulcerative Colitis (UC)
NEW YORK--(BUSINESS WIRE) October 13, 2023 – Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Velsipity™ (etrasimod), an oral, once-daily, s...
Autoimmune, Autoinflammatory Connective Tissue Disorders Increased After COVID-19
TUESDAY, Oct. 10, 2023 – COVID-19 is associated with an increased risk for autoimmune and autoinflammatory connective tissue disorders, according to a study published online Oct. 6 in JAMA Network...
FDA Grants Interchangeable Designation to Pfizer’s Biosimilar Abrilada
NEW YORK, October 5, 2023 – Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has designated Abrilada™ (adalimumab-afzb) as an interchangeable biosimilar to Hum...
Inflammatory Bowel Disease Tied to Higher Risk for Gout
TUESDAY, Oct. 3, 2023 – Inflammatory bowel disease (IBD) is strongly associated with gout, according to a study published online Sept. 1 in JGH Open. Osama Hamid, M.B.B.S., from the Cleveland...
U.S. FDA Approves Subcutaneous Administration of Takeda's Entyvio (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
OSAKA, Japan and CAMBRIDGE, Massachusetts, September 27, 2023 – Takeda today announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) administration of Entyvio® (v...
5-ASA Discontinuation Common Within First Year of Ulcerative Colitis Diagnosis in Youth
WEDNESDAY, Sept. 20, 2023 – For adolescents and young adults diagnosed with ulcerative colitis (UC), the rate of discontinuation of 5-aminosalicylic acid (5-ASA) maintenance treatment is high within...
Statin Use Linked to Reduced Risk for CRC Incidence, Mortality in Patients With IBD
THURSDAY, Sept. 7, 2023 – For patients with inflammatory bowel disease (IBD), statin use is associated with a reduced risk for colorectal cancer (CRC) incidence and mortality, according to a study...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Related drug support groups
Humira, clonidine, hydrocortisone, Remicade, Xeljanz, Entyvio, Stelara, Skyrizi, adalimumab, dexamethasone, budesonide